Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why would they do that? Unlike growing tobacco without nicotine, it takes absolutely no effort to produce vape juice without nicotine, and most juice you can buy likely already has a no nicotine variety on the market. Literally anyone can do it, it makes no sense to compete in that space.
It would be nice if we were growing hemp there this season, as far as I know there haven't been any press releases that confirm that.
But the company had a different CEO while it was still public prior to Henry. Anyway, I think we've upgraded CEOs but only time will tell.
Censoring opinions you don't agree with is not acceptable.
That's too soon, imo.
It's a pretty good read highlighting some fairly questionable stuff. Interested in seeing if any of it can be disproved.
Because it's cryptic.
Thank you :).
I'm still learning to read these so I need some clarification. How exactly do we get to a -7.9M loss from 26.4M in revenue? Operating expenses are 23.5M, but I don't see anything else accounting for the rest. Who wants to drop some accounting knowledge on me?
Good prediction, Perker. :(
Seeking Alpha Article
Good article. Uninformed on the nicotine side of things but respectable otherwise.
What addiction? They're VLN.
This is not a good investment strategy, but good luck.
That's not a horrible way to play this.
Because if hemp is legal in any form, XXII patents for it hold no rational value in the US.
No thanks, I'll sit here and observe rational market fluctuations. Thanks.
No it's not. That's literally not how the market works.
I do very much hope you're right and that the Phase III trials comes out as we expect it. While not a direct revenue generator, maybe it will stimulate the sale some more research cigs to keep the company from losing too much money while we wait.
I agree that they'll be fine and able to keep operating for a while, I just also don't see any reason for the share price to increase in the short term.
I like that they are maintaining and that the increase in income covers the increase to expenses. I don't like that their future income will probably go down because they no longer sell Red Sun, while expenses will likely keep increasing. If they don't come up with some new revenue streams this year, the stock price will take a hit. At least they have enough cash to keep afloat, but no deals means no catalysts for shareholder value.
So what do you guys think about the annual report?
There is literally nothing wrong with doing any of that. Stop complaining and play the game.
MO sells their products here, PM does not.
The FDA literally has no jurisdiction as it is a US based organization. This isn't really up for debate.
PM doesn't care what the FDA thinks.
I wouldn't mind.
That's what I keep saying, but no one appreciates a good hit piece anymore.
While that does sound like a cool read, the content seems to very blatantly describe: "breaking the law", haha.
There's money to be made in every direction :).
One point I will admit I find concerning is the reference in the article to just how much the company was relying on Red Sun sales. We'll have to watch the next few earnings closely now that they've ceased selling them.
Sure, it was misleading and mostly crap. However, that article did what it was supposed to do very well. We can now capitalize on the opportunity it helped create if we choose to and all it cost us is some temporary paper losses and a bit of discomfort. This is investing as it always has been. Investors unwilling to entertain this kind of manipulation should stick to index funds and out of small caps :).
The author crafted the article with purpose and intent, like a good analyst. His goals just don't align with your goals :). If he was forced to contact the company for comment, his goals would be much harder to achieve. Plus much like both of us, at the end of the day he's just a random person on the internet and everything stated is our responsibility to confirm and analyze.
There is absolutely no precedent forcing a stranger to tell you the truth at any point in time, written or spoken, unless that stranger is under oath or contract.
While somewhat pathetic, I prefer living in a society where these types of messages are protected and I have the freedom and ability to discredit them without reprise. The alternative gets messy :).
This article is very well written. It's obvious that it was done by someone who closely follows the company and knows exactly which buttons to press to drive down the share price in the short term. Well done. I personally believe the author wants to capitalize off the fact that XXII is overbought to drive the share price down heavily to purchase more in advance of the conclusion of the March phase III clinical trial.
The share price will go down in the near term, that is almost certainly a fact. Stop complaining about it. Wait a little while, and if you still believe in XXII, buy more while it's on sale, just don't wait too long or you won't get to profit off of what I predict to be a positive clinical trial result. Anything under 2 is a damn steal if we get there again.
Yay, my 3.03 trading shares got filled. XXII can go back to $4 now.
Fluff news to let us know someone is still at the helm. I coulda waited, less news means my limit at 3.03 is more likely to get hit.
Okay now we can get along again ^^. SA is the foundation for the majority of my investing knowledge over the past half decade, so I get a little defensive :-P.